论文信息 - Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck - 字舞流文

Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

E. Vokes | D. Huo | E. Cohen | M. Kane | B. Mehrotra | M. List | A. Mauer | B. Brockstein | A. Dekker | C. Pierce